List of Novavax patents

Patents where

Current Assignee

Name

Novavax

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 10953089 Coronavirus vaccine formulations	Patent 10953089 was granted and assigned to Novavax on March, 2021 by the United States Patent and Trademark Office.	Novavax	Novavax	United States Patent and Trademark Office	10953089	March 23, 2021
‌ US Patent 9050290 Functional influenza virus like particles (VLPs)	Patent 9050290 was granted and assigned to Novavax on June, 2015 by the United States Patent and Trademark Office.		Novavax	United States Patent and Trademark Office	9050290	June 9, 2015
‌ US Patent 10426829 Vaccine compositions having improved stability and immunogenicity	Patent 10426829 was granted and assigned to Novavax on October, 2019 by the United States Patent and Trademark Office.	Novavax	Novavax	United States Patent and Trademark Office	10426829	October 1, 2019
‌ US Patent 11253585 Vaccine compositions having improved stability and immunogenicity	Patent 11253585 was granted and assigned to Novavax on February, 2022 by the United States Patent and Trademark Office.	Novavax	Novavax	United States Patent and Trademark Office	11253585	February 22, 2022
‌ US Patent 9381239 VLPS derived from cells that do not express a viral matrix or core protein	Patent 9381239 was granted and assigned to Novavax on July, 2016 by the United States Patent and Trademark Office.	Novavax	Novavax	United States Patent and Trademark Office	9381239	July 5, 2016
‌ US Patent 11278612 Multivalent influenza nanoparticle vaccines	Patent 11278612 was granted and assigned to Novavax on March, 2022 by the United States Patent and Trademark Office.	Novavax	Novavax	United States Patent and Trademark Office	11278612	March 22, 2022
‌ US Patent 10022437 Modified RSV F proteins and methods of their use	Patent 10022437 was granted and assigned to Novavax on July, 2018 by the United States Patent and Trademark Office.	Novavax	Novavax	United States Patent and Trademark Office	10022437	July 17, 2018
‌ US Patent 11123419 Methods and compositions for inducing immune responses against Clostridium difficile	Patent 11123419 was granted and assigned to Novavax on September, 2021 by the United States Patent and Trademark Office.	Novavax	Novavax	United States Patent and Trademark Office	11123419	September 21, 2021
‌ US Patent 11541112 Coronavirus vaccine formulations	Patent 11541112 was granted and assigned to Novavax on January, 2023 by the United States Patent and Trademark Office.	Novavax	Novavax	United States Patent and Trademark Office	11541112	January 3, 2023
‌ US Patent 11052146 Modified RSV F proteins and methods of their use	Patent 11052146 was granted and assigned to Novavax on July, 2021 by the United States Patent and Trademark Office.	Novavax	Novavax	United States Patent and Trademark Office	11052146	July 6, 2021
‌ US Patent 9717786 Modified RSV F proteins and methods of their use	Patent 9717786 was granted and assigned to Novavax on August, 2017 by the United States Patent and Trademark Office.	Novavax	Novavax	United States Patent and Trademark Office	9717786	August 1, 2017
‌ US Patent 9731000 Modified RSV F proteins and methods of their use	Patent 9731000 was granted and assigned to Novavax on August, 2017 by the United States Patent and Trademark Office.	Novavax	Novavax	United States Patent and Trademark Office	9731000	August 15, 2017
‌ US Patent 11364294 Vaccine compositions having improved stability and immunogenicity		Novavax	Novavax	United States Patent and Trademark Office	11364294	June 21, 2022
‌ US Patent 11446374 Modified RSV F proteins and methods of their use		Novavax	Novavax	United States Patent and Trademark Office	11446374	September 20, 2022
‌ US Patent 8715692 Modified RSV F proteins and methods of their use	Patent 8715692 was granted and assigned to Novavax on May, 2014 by the United States Patent and Trademark Office.		Novavax	United States Patent and Trademark Office	8715692	May 6, 2014
‌ US Patent 9675685 Modified RSV F proteins and methods of their use	Patent 9675685 was granted and assigned to Novavax on June, 2017 by the United States Patent and Trademark Office.	Novavax	Novavax	United States Patent and Trademark Office	9675685	June 13, 2017
‌ US Patent 11253586 Coronavirus vaccine formulations	Patent 11253586 was granted and assigned to Novavax on February, 2022 by the United States Patent and Trademark Office.	Novavax	Novavax	United States Patent and Trademark Office	11253586	February 22, 2022
‌ US Patent 9464276 Highly efficient influenza matrix (M1) proteins	Patent 9464276 was granted and assigned to Novavax on October, 2016 by the United States Patent and Trademark Office.	Novavax	Novavax	United States Patent and Trademark Office	9464276	October 11, 2016
‌ US Patent 9623104 Functional influenza virus-like particles (VLPS)	Patent 9623104 was granted and assigned to Novavax on April, 2017 by the United States Patent and Trademark Office.	Novavax	Novavax	United States Patent and Trademark Office	9623104	April 18, 2017
‌ US Patent 9694066 Functional influenza virus like particles (VLPs)	Patent 9694066 was granted and assigned to Novavax on July, 2017 by the United States Patent and Trademark Office.	Novavax	Novavax	United States Patent and Trademark Office	9694066	July 4, 2017
‌ US Patent 9937253 Functional influenza virus-like particles (VLPS)	Patent 9937253 was granted and assigned to Novavax on April, 2018 by the United States Patent and Trademark Office.	Novavax	Novavax	United States Patent and Trademark Office	9937253	April 10, 2018
‌ US Patent 10188723 Functional influenza virus like particles (VLPs)	Patent 10188723 was granted and assigned to Novavax on January, 2019 by the United States Patent and Trademark Office.	Novavax	Novavax	United States Patent and Trademark Office	10188723	January 29, 2019
‌ US Patent 9474799 Functional influenza virus-like particles (VLPS)	Patent 9474799 was granted and assigned to Novavax on October, 2016 by the United States Patent and Trademark Office.	Novavax	Novavax	United States Patent and Trademark Office	9474799	October 25, 2016
‌ US Patent 9956280 Functional influenza virus-like particles (VLPs)	Patent 9956280 was granted and assigned to Novavax on May, 2018 by the United States Patent and Trademark Office.	Novavax	Novavax	United States Patent and Trademark Office	9956280	May 1, 2018
‌ US Patent 10729760 Functional influenza virus like particles (VLPs)	Patent 10729760 was granted and assigned to Novavax on August, 2020 by the United States Patent and Trademark Office.	Novavax	Novavax	United States Patent and Trademark Office	10729760	August 4, 2020

Results per page:

37 results

0 selected

37 results

0 selected